Obstetricians and endocrinologists know gestational diabetes typically surfaces between 24-28 weeks, but the STRiDE study from South India reveals early gestational diabetes diagnosed before 20 weeks affects 21.5% of pregnant women—nearly matching the 19.5% late-onset rate—and carries distinct risk factors that demand earlier screening protocols in high-risk Asian populations.
The results were published in the Diabetes Research and Clinical Practice. Researchers in the prospective STRiDE cohort enrolled 3,070 pregnant women before 16 weeks gestation across seven antenatal clinics, with 2,703 undergoing early fasting plasma glucose testing. 
Women with normal FPG below 92 mg/dL proceeded to standard OGTT at 24-28 weeks, classifying participants into early GDM (FPG 92-125 mg/dL), late GDM (normal early FPG but abnormal OGTT), or normal glucose tolerance groups.
Early Screening Uncovers Hidden Prevalence
The balanced 21.5% early GDM versus 19.5% late GDM rates challenge traditional timing assumptions, showing nearly 41% of pregnancies develop hyperglycemia when universal early testing occurs before 16 weeks, far exceeding global averages and highlighting South Indian women's unique susceptibility.
Metabolic Markers Differ Sharply
Women with early GDM presented heavier at 63.9 kg versus 61.2 kg in late GDM, carried higher BMI of 25.8 kg/m² versus 25.0 kg/m², showed elevated HbA1c of 5.3% versus 5.1%, and reported more frequent prior GDM history at 8.5% versus 5.3%, painting a picture of preexisting metabolic strain unmasked by early pregnancy testing rather than gestational onset.
Risk Factors Split by Timing
Prior GDM history specifically predicted early GDM, while family history of diabetes drove late GDM risk, suggesting early cases represent overt pre-pregnancy dysglycemia and late cases reflect progressive beta-cell stress under pregnancy demands, which determines who needs immediate intervention.
Antenatal Protocols Need Urgent Update
In the first-trimester patient from South Asia with prior GDM or BMI over 25, the physicians may order FPG at the first visit, as STRiDE proves early GDM prevalence rivals late cases and demands metformin or insulin titration before 20 weeks to protect fetal growth and maternal outcomes.
Population-Specific Screening Pays Off
South Indian data underscore universal early screening feasibility in high-prevalence regions, potentially halving undiagnosed hyperglycemia exposure during organogenesis when congenital risks peak.